Variability of Fluconazole Concentration in Critically Ill Patients

Status Completed

Clinical Trial Summary

Fluconazole is the first-line agent in the treatment of invasive candidiasis. Studies showed inappropriate drug exposure causes high mortality in critically ill patients. Under-dosing and ineffective fluconazole trough serum concentrations were found in a recent retrospective study. Variability in fluconazole exposure can be easily measured with therapeutic drug monitoring. For patient groups who are at risk for drug underexposure, therapeutic drug monitoring can be valuable regards decreasing mortality.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02491151
Study type	Observational
Source	University Medical Center Groningen
Contact
Status	Completed
Phase	N/A
Start date	October 2014
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05763251` - Comparison of Uncomplicated Candidemia Therapy Duration in Children	N/A
Recruiting	`NCT01438216` - Anidulafungin Pharmacokinetics in Intensive Care Unit Patients	N/A
Terminated	`NCT01213823` - Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins	Phase 4
Completed	`NCT01716988` - Pharmacokinetics of Micafungin in Critically Ill Patients	N/A
Completed	`NCT00607763` - Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug	Phase 1
Completed	`NCT00608335` - Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug	Phase 1
Completed	`NCT00786903` - Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?	N/A
Completed	`NCT00670657` - CRITIC - Treatment of Candidemia and Invasive Candidiasis	Phase 4
Recruiting	`NCT04368559` - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation	Phase 3
Not yet recruiting	`NCT05707832` - A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus	Phase 3
Recruiting	`NCT03538912` - Early Discontinuation of Empirical Antifungal Therapy and Biomarkers	N/A
Completed	`NCT02801682` - NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
Completed	`NCT02164890` - Pharmacokinetics of Micafungin in Patients of Intensive Care Units	Phase 4
Completed	`NCT02841501` - Genetic Susceptibility Factors for Candidemia.
Completed	`NCT01047267` - Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)	N/A
Completed	`NCT00672841` - β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients	N/A
Completed	`NCT02734862` - CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension	Phase 2
Completed	`NCT01773876` - Empirical Antifungal Treatment in ICUS	Phase 3
Completed	`NCT00689338` - Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study	Phase 3
Terminated	`NCT03906916` - Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin	Phase 4